2019 RORgamma Antagonists and Agonists Competitor Analysis - ResearchAndMarkets.com

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Oct 18, 2019 11:33 am
DUBLIN -- 

The "Competitor Analysis: RORgamma Antagonists and Agonists" report has been added to ResearchAndMarkets.com's offering.

This Competitive Intelligence report about RORgamma Antagonists and Agonists evaluates the landscape of investigational small molecules targeting the Retinoic Acid-Related Orphan Receptor gamma (ROR) for treatment of inflammatory diseases and cancer as of September 2019.

The transcription factor ROR plays a critical role in the expression of pro-inflammatory cytokine interleukin IL-17 and is, therefore, an attractive target for the treatment of inflammatory diseases. Interest in this molecular target has been heightened by the advancement of orally and topically administered ROR modulators into clinical trials.

Some studies found ROR to be upregulated in cancer tissues compared with normal tissues. Furthermore, synthetic ROR agonists modulate immune cell gene expression to increase effector T-cell activity and decrease immune suppression

The report includes a compilation of currently active projects in research and development of RORgamma antagonists and agonists for the treatment of inflammatory diseases and cancer, respectively. In addition, the report lists company-specific R&D pipelines of antagonists and agonists of RORgamma.

Competitor projects are listed in a tabular format providing information on:

  • Drug Codes
  • Target / Mechanism of Action
  • Class of Compound
  • Company
  • Product Category
  • Indication
  • R&D Stage and additional comments with a hyperlink leading to the source of information.

Key Topics Covered:

  • RORgamma Antagonists / Inverse Agonists for Inflammatory Diseases
  • RORgamma Agonists for Cancer
  • Corporate RORgamma Antagonist & Agonist R&D Pipelines

For more information about this report visit https://www.researchandmarkets.com/r/od29t7

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).